ACCC approves Pfizer's pending acquisition of Wyeth

Sep 30 2009

Pfizer Inc (NYSE:PFE) today announced that the Australian Competition and Consumer Commission (ACCC) has approved the company’s pending acquisition of Wyeth. The ACCC’s decision includes Pfizer’s commitment to divest certain animal health assets in Australia.

“We are pleased to have achieved another significant milestone this week with the ACCC’s approval of the pending acquisition,” said Jeff Kindler, chairman and chief executive officer, Pfizer. The transaction remains subject to regulatory approval in the United States and Canada. Pfizer expects to obtain these approvals shortly and to close the transaction early in the fourth quarter 2009.

Source:

Pfizer Inc.

Posted in:

Comments (0)

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback